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Abstract: Antibiotic resistance is a major global health concern. 
There is a significant and urgent need for the development of novel 
antimicrobials to tackle the increasing incidence of antibiotic 
resistance. Recently, phenylglyoxamide-based small molecular 
antimicrobial peptide mimics have been identified as potential new 
leads to treat bacterial infection. Here, we describe the synthesis of 
novel phenylglyoxamide derivatives via the ring-opening reaction of 
N-sulfonylisatins with primary amines, followed by conversion into 
hydrochloride (HCl), quaternary ammonium iodide or guanidine salts. 
The antibacterial activity of the compounds against Staphylococcus 
aureus was evaluated in vitro by a disk diffusion assay and a minimum 
inhibitory concentration (MIC) assay. Structure-activity relationship 
studies revealed that a 5-bromo-substituent at the phenyl ring, octyl 
group appended to the ortho sulfonamide group or a guanidine 
hydrochloride salt as the terminal group significantly contributed to 
potency. The most potent compound in this study, the guanidine salt 
35d, exhibited an MIC value of 12 µM. The most active compounds 
induced an increase in membrane conduction, suggesting that they 
are potential antimicrobial pore-forming agents. The compounds had 
therapeutic indices ranging from 0.8 to 15. Overall, the results 
identified 35d as a new lead antimicrobial compound that possesses 
an acceptable therapeutic window. 
Introduction 
Infectious diseases caused by bacteria are one of the leading 
causes of death worldwide.[1] The discovery of the powerful 
bactericidal agent, beta-lactam (penicillin), in the 1930s provided 
an effective strategy to treat bacterial infection.[2] Different classes 
of antibiotics target different metabolic processes in bacteria, 
such as inhibition of bacterial cell wall synthesis, protein synthesis, 
DNA and RNA synthesis, fatty acids biosynthesis, folate synthesis, 
or depolarizing bacterial cell membrane potentials.[3]  
However, the use of conventional antibiotics can exert 
selective survival pressure on bacteria, leading to the 
development of drug resistance. The most common antibiotic 
resistance mechanism is the enzymatic inactivation of antibiotics, 
whereby metabolic enzymes produced by bacteria metabolise 
antibiotics into their inactive form. For instance, beta-lactam 
antibiotics are inactivated by beta-lactamase enzymes, which 
hydrolyse the amide group and cleave the beta-lactam ring.[4] 
Other antibiotic resistance mechanisms involve mutations at the 
binding sites so that the antibiotics has reduced affinity, or 
physical removal of the antibiotic from the bacterial cell by efflux 
pumps.[5]  
The misuse and overuse of antibiotics has accelerated the 
development of antibiotic resistance.[6] Moreover, with typical 
antibiotic development strategies relying heavily on merely 
modifying the periphery of existing antibiotic scaffolds, resistance 
to one antibiotic can rapidly spread to other antibiotics within the 
same class as they share a common core.[7]  
Antibiotic-resistant bacteria cause more than 23,000 deaths in the 
US every year.[8] Alarmingly, multi-drug resistant bacterial strains 
have emerged that are resistant to all known antibiotics.[9] 
Therefore, there is an urgent need to develop novel and 
efficacious therapies to treat bacterial infection, particularly those 
caused by drug-resistance strains. 
Antimicrobial peptides (AMPs) are naturally occurring 
amphipathic peptides found in most living organisms, including 
humans.[10] They play an important role as the first line of defence 
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in our immune system and protect us against a wide variety of 
pathogenic organisms, such as bacteria, fungi, protozoa, yeast 
and viruses.[11] AMPs are typically 12 to 50 amino acids in length 
and contain both hydrophilic (cationic) and hydrophobic 
residues.[10a] They possess rigid secondary alpha-helix or beta-
sheet structures with the hydrophilic cationic residues located on 
one face of the molecule and hydrophobic residues on the 
opposite face.[1, 10a, 11a, 12] Unlike traditional antibiotics, AMPs do 
not act via enzyme or receptor interactions. Instead, they kill 
pathogens by disrupting their membrane integrity, causing the 
leakage of cellular components or the loss of membrane potential, 
both resulting in cell death.[13] The ability of AMPs to disrupt 
membranes is predominately attributed to their facially 
amphiphilic structure.[11a] The hydrophilic cationic residues on one 
face of the AMP initially bind electrostatically to the negatively-
charged bacterial cell membrane. Once the AMP is bound, the 
hydrophobic residues on the opposite face assist in the insertion 
of the molecule into the bacterial cell membrane, causing the 
formation of pores in the bacterial cell membrane.[11a, 12, 14] As 
AMPs kill bacteria via disrupting bacterial cell membranes, a 
complete restructuring of the bacterial outer cell membrane would 
be required for bacteria to develop resistance to AMPs.[11a, 13c] 
More importantly, AMPs have a high degree of selectivity towards 
bacterial cells over human cells, which can be attributed to the 
difference in the lipid composition between the two types of cell 
membranes.[15] While the extracellular side of the human lipid 
bilayer is mainly composed of zwitterionic phospholipids such as 
phosphatidylcholine with only a minute amount of negatively-
charged lipids, the bacterial cell membrane contains a significant 
portion of negatively-charged lipids, increasing their affinity 
towards AMPs.[13b, 15-16] AMPs have thus attracted attention as 
potential therapeutic agents to combat bacterial infection that are 
resistant to conventional antibiotics. 
Although AMPs can exhibit potent and selective 
antibacterial activity, they have several drawbacks. Firstly, the 
synthesis of AMPs involves a high manufacturing cost. Due to the 
antibacterial nature of AMPs, it is difficult to use bacterial 
fermentation methods for synthesis. Current production 
methodologies are based on solid-phase peptide synthesis, which 
requires expensive precursor components and extensive 
purification, but only produces AMPs in low yield.[17] Furthermore, 
AMPs are susceptible to protease hydrolysis. Proteases in the 
serum can cleave the peptide bonds in AMPs, reducing the 
metabolic stability of AMPs in vivo.[18] The drawbacks of AMPs 
have stimulated the development of AMP mimics, such as α-
peptides and β-peptides.[19] In addition, several small molecule 
AMP mimics (e.g. 1 and 2) have shown high antimicrobial 
activities against a variety of bacterial strains (Figure 1).[15, 20] 
LTX-109 3 is now in Phase-II clinical trials for the topical treatment 
of multi-drug resistant Gram-positive and Gram-negative 
bacteria.[21] 
N-Aryl, N-acyl or N-sulfonylisatins 4 (Figure 2) can undergo 
ring-opening reaction with alcohols and amines to yield the 
corresponding phenylglyoxamide.[22] Recently, our research 
group has reported that N-naphthoyl-phenylglyoxamide 
derivatives 5 (Figure 2), possess moderate to high antibacterial 
activities against the common bacterial pathogens 
Staphylococcus aureus and Pseudomonas aeruginosa.[22b] These 
phenylglyoxamides can be synthesised by the ring-opening 
reaction of N-sulfonylisatin with amines. As the effect of varying 
the N-substituent appended to ortho amino group on the activity 
of these compounds has not been explored, it is of great interest 
to synthesise novel N-sulfonyl-phenylglyoxamide derivatives as 
potential antibacterial agents. 
 
Figure 2. Structures of N-substituted isatins 4 and N-naphthoyl-
phenylglyoxamide derivatives 5. 
 
Figure 1. Chemical structures of AMP mimics 1-2 and LTX-109 3.[15, 20a, 21b]. 
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In this study, we report the synthesis of novel N-sulfonyl-
phenylglyoxamide derivatives as small molecular AMP mimics. 
First, a panel of N-sulfonylisatins were synthesized via a simple 
and time-efficient method. Subsequently, the N-sulfonylisatins 
were ring-opened with diamines (N,N-dimethylethane-1,2-
diamine or N,N-dimethylpropane-1,3-diamine) to give the 
corresponding phenylglyoxamide derivatives. Finally, these were 
converted into their hydrochloride or iodide salts to give the 
desired AMP mimics. In addition, N-octanesulfonylisatin and N-
naphthalenesulfonylisatin were also ring-opened with tert-butyl N-
(3-aminopropyl)carbamate followed by installation of the 
guanidine moiety to furnish AMP mimics with an alternative 
cationic group. 
The N-sulfonyl-phenylglyoxamide derivatives are 
amphipathic in nature due to the presence of both the 
hydrophobic groups at the N-sulfonyl position, and the hydrophilic 
ammonium or guanidine hydrochloride salts at the end of the 
glyoxamide chain (Figure 3). The synthesised compounds were 
evaluated for their antimicrobial potency against two common 
bacterial pathogens S. aureus and P. aeruginosa. Selected 
analogues with high antibacterial activity were tested for their 
ability to disrupt bacterial membrane integrity using tethered 
bilayer lipid membranes. Finally, their cytotoxicity against normal 
mammalian cells was also evaluated by using the Alamar Blue 
assay. 
 
Figure 3. General structure of N-sulfonyl-phenylglyoxamide-based small 
molecular AMP mimics. 
Results and Discussion 
Synthesis 
Initially, the synthesis of N-sulfonylisatins followed a modified 
version of the procedure described by Chin et al. in 2002,[23] in 
which isatin 6 was converted into its sodium salt by stirring with 
1.2 equivalents of sodium hydride in dimethylformamide (DMF) at 
0 °C for 20 min under a nitrogen atmosphere. An appropriate 
sulfonyl chloride was then added dropwise with stirring to the 
purple reaction mixture. After 18 h of stirring at room temperature, 
thin layer chromatography (TLC) confirmed the formation of 
product. The orange reaction mixture was poured into an ice-
water mixture and the precipitate was filtered to give an orange 
solid. However, after washing the crude solid with methanol, only 
poor yields (0-17%) of the N-sulfonylisatin products were obtained.  
 A modified version of the synthetic scheme described by 
Chung et al. in 2003 was then attempted in the synthesis of N-
sulfonylisatins.[24] This method utilises milder reaction condition, 
and was reported to produce a moderate to high yield of the 
product in a time-efficient manner. In this method, a mixture of the 
appropriate isatin 6 and an appropriate sulfonyl chloride was 
stirred with triethylamine in dichloromethane (DCM) at room 
temperature for 3-24 h under a nitrogen atmosphere. This 
afforded N-sulfonylisatins 7-18 in 23-86% yields (Scheme 1, 
Table 1). Although this method gave moderate to high yield of the 
N-sulfonylisatin products, some of the compounds were lost when 
washing the crude product with methanol as evidenced by TLC. 
In an attempt to improve upon this, flash column chromatography 
on silica (ethyl acetate/n-hexane = 1:4) was used to purify the 
crude product 8 instead. However, this gave only a 3% yield of 
the pure product 8, and some of the product also co-eluted with 
isatin despite the good separation of the two species on the TLC 
plate. This could be explained by the poor solubility of isatin and 
N-sulfonylisatin 8 in the ethyl acetate/n-hexane mixture. 
Therefore, washing the crude with methanol was deemed to be 
the most suitable purification method for the synthesis of N-
sulfonylisatins in terms of both time and yield.[22a] 
 
Scheme 1. Synthesis of N-sulfonylisatins 7-18. 
Table 1. Yields of synthesised N-sulfonylisatins. 
Entry R1  R2  N-sulfonylisatin (yield) 
1 H Phenyl 7 (86%) 
2 H 4-Tolyl 8 (78%) 
3 H Octyl 9 (50%) 
4 H Butyl 10 (50%) 
5 Br Phenyl 11 (52%) 
6 Br 4-Tolyl 12 (48%) 
7 Br Octyl 13 (51%) 
8 Br Butyl 14 (32%) 
9 Br 2-Naphthalenyl 15 (26%) 
10 Cl Octyl 16 (50%) 
11 F Octyl 17 (23%) 
12 Me Octyl 18 (64%) 
  
After the successful synthesis of N-sulfonylisatins 7-18, the 
ring-opening reactions were performed by reacting N-
sulfonylisatins 7-18 with either N,N-dimethylethane-1,2-diamine 
or N,N-dimethylpropane-1,3-diamine in dichloromethane at room 
temperature for 1-24 h to afford the novel phenylglyoxamide 
derivatives 19a-33a in 95-99% yields (Scheme 2, Table 2). 
 




Scheme 2. Synthesis of hydrochloride salts 19b-33b and iodide salts 19c-33c from N-sulfonylisatins 7-18. Reaction conditions: (a) DCM, rt, 1-24 h; (b) 4 M 
HCl/dioxane, DCM/diethyl ether, rt, 20 min-6 h; (c) CH3I, DCM/THF, rt, 14-48 h. 
Table 2. Yields of synthesised glyoxamide derivatives, hydrochloride salts and iodide salts. 





Iodide salt (yield) 
1 H Phenyl 2 19a (99%) 19b (97%) 19c (99%) 
2 H 4-Totyl 2 20a (97%) 20b (100%) 20c (94%) 
3 H Octyl 1 21a (98%) 21b (90%) 21c (82%) 
4 H Octyl 2 22a (96%) 22b (70%) 22c (81%) 
5 H Butyl 2 23a (99%) 23b (100%) 23c (99%) 
6 Br Phenyl 2 24a (95%) 24b (99%) 24c (100%) 
7 Br 4-Totyl 2 25a (99%) 25b (85%) 25c (87%) 
8 Br Octyl 1 26a (97%) 26b (88%) 26c (97%) 
9 Br Octyl 2 27a (97%) 27b (94%) 27c (100%) 
10 Br Butyl 2 28a (99%) 28b (100%) 28c (72%) 
11 Br 2-Naphthalenyl 1 29a (97%) 29b (67%) 29c (98%) 
12 Br 2-Naphthalenyl 2 30a (97%) 30b (85%) 30c (83%) 
13 Cl Octyl 2 31a (97%) 31b (93%) 31c (86%) 
14 F Octyl 2 32a (95%) 32b (60%) 32c (79%) 
15 Me Octyl 2 33a (97%) 33b (80%) 33c (63%) 
 
The phenylglyoxamide compounds were then converted to 
the corresponding ammonium salts by treatment with either HCl 
or methyl iodide. For the formation of hydrochloride salts 19b-33b, 
phenylglyoxamide derivatives 19a-33a were treated with 4 M 
hydrogen chloride/dioxane in dichloromethane or diethyl ether at 
room temperature for 20 min to 6 h. The yellow reaction mixture 
was then concentrated in vacuo to remove the solvent and excess 
hydrogen chloride/dioxane solution, and the precipitated crude 
product was washed with diethyl ether to remove unreacted 
phenylglyoxamide starting material, affording the hydrochloride 
salts 19b-33b in 60-100% yields (Scheme 2, Table 2). 
 Similarly, the synthesis of the iodide salts 19c-33c involved 
the reaction of phenylglyoxamide derivatives 19a-33a with 
iodomethane in either dichloromethane or tetrahydrofuran (THF) 
at room temperature for 14-48 h. The reaction mixture was then 
concentrated in vacuo to remove the solvent and excess 
iodomethane, and the precipitated crude product was washed 
with diethyl ether to remove phenylglyoxamide starting material to 
afford iodide salts 19c-33c in 63-100% yields (Scheme 2, Table 
2). 
 We also investigated the installation of the guanidine group 
at the end of the glyoxamide chain of analogues, in place of the 
tertiary or quaternary ammonium group. The first step of the 
reaction sequence involved the ring-opening of 1-
octanesulfonylisatins 9 and 13 and 2-naphthalenesulfonylisatin 
15 with tert-butyl N-(3-aminopropyl)carbamate in 
dichloromethane at room temperature for 15-21 h, which afforded 
glyoxamide derivatives 34a-36a in 97-98% yields (Scheme 3, 
Table 3). Solutions of the glyoxamide derivatives 34a-36a in 
dichloromethane were then treated with 4 M hydrogen 
chloride/dioxane at room temperature for 18 h to cleave the Boc 
group and liberate the amine functionality. After full conversion of 
starting material to product, as evidenced by TLC, the solvent and 
unreacted reagents were removed in vacuo and the residue was 
washed with diethyl ether to remove traces of starting material 
and impurities to afford aminoglyoxamide hydrochloride salts 
34b-36b in 82-87% yields.




Scheme 3. Synthetic route for the synthesis of guanidine hydrochloride salts 34d-36d. 
Table 3. Yields of synthesised guanidine hydrochloride salts and their corresponding intermediates. 









1 H Octyl 34a (98%) 34b (82%) 34c (33%) 34d (71%) 
2 Br Octyl 35a (98%) 35b (83%) 35c (51%) 35d (72%) 
3 Br 2-Naphthalenyl 36a (97%) 36b (87%) 36c (36%) 36d (67%) 
 
 The aminoglyoxamide hydrochloride salts 34b-36b were 
converted to the free amine by treatment with 2.5 equivalents of 
triethylamine, and then reacted with 1.0 equivalent of N,N'-di-Boc-
1H-pyrazole-1-carboxamidine in dichloromethane at room 
temperature for 15-18 h to give the Boc-protected guanidine 
glyoxamides 34c-36c. The Boc-protected guanidine glyoxamide 
34c could be isolated in 33% yield after purification by flash 
column chromatography on silica, however, analogues 35c-36c 
were isolated in a very poor yield of 3% using the same procedure 
(Scheme 4, Table 4). We observed that during the synthesis of 
glyoxamide 35c, a significant amount of white precipitate was 
found in the reaction mixture, which was removed by filtration 
before column chromatography. This white precipitate was not 
observed during the synthesis of analogue 34c. NMR 
spectroscopy study revealed that the identity of the white 
precipitate was not the aminoglyoxamide 35b starting material, as 
evidenced by the absence of a broad amine singlet peak 
integrating to 2 protons. Moreover, the spectrum of the white 
precipitate lacked hydrochloride signals. This led to the 
hypothesis that instead of reacting with N,N'-di-Boc-1H-pyrazole-
1-carboxamidine, the terminal amine group of aminoglyoxamide 
35b reacted instead with the carbonyl group of the glyoxamide 
moiety of another molecule of aminoglyoxamide 35b, to form the 
dimeric imine product 37 (Figure 4). The formation of dimer was 
confirmed by the high-resolution mass spectrum of the white 
precipitate, which showed a molecular peak at m/z 939.1939 that 
was consistent with the molecular formula C38H56Br2N6O6S2Na 
([M+Na]+ required 939.1941). The corresponding dimeric product 
could have also been formed in the synthesis of analogue 34c, 
however, due to its higher solubility in dichloromethane, it may not 
have precipitated out of the reaction mixture. With the identity of 
the dimeric side product determined, the reaction conditions (such 
as solvent, different amount and type of base and amount of N,N'-
di-Boc-1H-pyrazole-1-carboxamidine) for the synthesis of 35c 
were optimised (Table 4). The results showed that the use of 
acetonitrile as a solvent gave the highest yield of product 35c in 
this reaction. The optimised conditions (Entry 6) were then also 
applied to aminoglyoxamide 36b, producing Boc-protected 
guanidine glyoxamide 36c in 36% yield. 
 
Figure 4. Chemical structure of compound 37. 




Scheme 4. Synthesis of 35c (conditions are listed in Table 4) 
Table 4. Conditions tested for optimising the synthesis of 35c. 







1 2.5 eq. Et3N DCM 1.0 eq. 15 3 
2 2.5 eq. Et3N DCM 1.0 eq. 30 16 
3 1.0 eq. Et3N DCM 1.0 eq. 15 6 
4 2.5 eq. Et3N DCM 1.2 eq. 15 11 
5 2.5 eq. Et3N ACN 1.2 eq. 15 51 
6 2.5 eq. DIPEA ACN 1.2 eq. 15 51 
7 2.5 eq. DIPEA DMF 1.2 eq. 15 31 
 
Finally, Boc-protected guanidine glyoxamides 34c-36c were 
deprotected by reacting with trifluoroacetic acid in 
dichloromethane (1:1) at room temperature for 2 h. After the 
completion of reaction as monitored by TLC, the dichloromethane 
and excess trifluoroacetic acid were removed in vacuo and 
impurities were removed by washing the precipitated product with 
diethyl ether. An ion exchange reaction was then carried out by 
treating the trifluoroacetate salt with 4 M hydrogen 
chloride/dioxane in dichloromethane at room temperature for 30 
min. Dichloromethane and excess hydrogen chloride/dioxane 
solution were removed in vacuo and the impurities were again 
removed by washing the crude solid with diethyl ether to afford 
the guanidine hydrochloride salts 34d-36d in 67-72% yields. 
 The overall synthesis of the hydrochloride and iodide salts 
was achieved in only three steps from isatin and did not require 
any chromatographic purification. In the first step, N-
sulfonylisatins 7-18 were synthesised in moderate to high yields 
(48-86%) except compounds 14 (32%), 15 (26%) and 17 (23%). 
These compounds were isolated via washing with methanol and 
could be used in the next step without further purification. The 
ring-opening reactions of the N-sulfonylisatins produced 
glyoxamide derivatives 19a-33a that could be isolated in sufficient 
purity using simple aqueous work-up. Finally, the salt compounds 
19b-33c were also isolated as pure compounds via washing with 
diethyl ether. For the guanidine series, the intermediates 34-36a 
and 34b-36b as well as the targeted 34d-36d guanidine 
hydrochloride salts were all isolated either by filtration with 
washing or via aqueous work-up. The only compounds that were 
purified by column chromatography were the Boc-protected 
guanidine glyoxamides 34c-36c. 1H NMR was used to confirm the 
structure of all synthesised compounds, with the presence of the 
sulfonamide NH proton (δ 10-11) and the glyoxamide NH proton 
(δ 8-9) being characteristic for compounds of these series. This 
novel synthetic strategy therefore provides a new and efficient 
pathway for the synthesis of N-sulfonylisatins and their 
glyoxamide derivatives, allowing for the development and 
elucidation of structure-activity relationship (SAR) of glyoxamide-
based antibacterial agents. 
 
Antibacterial activity 
The antibacterial activity of the synthesised salt compounds 19b-
33c and 34d-36d was evaluated by the determination of zone-of-
inhibition diameter using the disk diffusion assay and minimum 
inhibitory concentration (MIC) values from the MIC assay. 
 
Disk diffusion assay 
The synthesized compounds 19b-33c and 34d-36d were first 
screened by using the disk diffusion assays against 
Staphylococcus aureus (SA38) and Pseudomonas aeruginosa 
(PAO1). In this assay, bacterial cultures were incubated overnight 
in tryptone soya broth (TSB) at 37 °C and the resulting bacterial 
cultures were spread onto nutrient agar plates. The compounds 
to be tested were administered to sterile 6 mm paper disks at 80 
nmol per disk as solutions in DMSO and dried. A well-known 
antibiotic, gentamicin (0.01 mg per disk) was used as positive 
control. The diameter of zone of inhibition was measured after 
incubation at 37 °C for 24 h (Table 5).  
In this assay, active analogues showed zones of inhibition 
ranging from 7 to 16 mm against S. aureus. The most active 
compounds against S. aureus in this assay were the guanidine 
hydrochloride salts 34d and 35d which showed zone of inhibition 
values of 16 and 15 mm against S. aureus respectively. However, 
none of the compounds synthesised showed antibacterial activity 
against the P. aeruginosa strain in the disk diffusion assay. 
The antibacterial potency of compounds cannot be 
determined quantitatively by the disk diffusion assay due to the 
different diffusion rates of compounds in agar. Therefore, 
compounds which showed activities in the disk diffusion assay 
were further analysed by determining their minimum inhibitory 
concentration (MIC) values. 
 
Minimum inhibitory concentration (MIC) assay 
Compounds that showed antibacterial activities in the disk 
diffusion assay were then tested in the minimum inhibitory 
concentration assay to quantitatively determine the concentration 
of compound required to inhibit bacterial growth in liquid media. 
In this assay, S. aureus SA38 in TSB was incubated with the 
compounds with final concentration ranging from 8-250 µM at 37 
°C for 24 h. The optical density (OD) value at 600 nm was then 
measured at the end of the 24 h period. The MIC value of each 
compound was determined as the lowest  
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Table 5. Zone of inhibition (in mm) and minimum inhibitory concentration (in µM) of compounds against S. aureus (SA38).  
Compound 










Zone of inhibition 
(mm) 
MIC (µM) 
    
19a – ND  19b – ND  19c – ND 
20a – ND  20b – ND  20c – ND 
21a 7 63  21b 7 250  21c 9 125 
22a 7 250  22b – ND  22c 9 250 
23a – ND  23b – ND  23c – ND 
24a – ND  24b – ND  24c – ND 
25a – ND  25b 7 >250  25c – ND 
26a 7 94  26b 10 63  26c 11 63 
27a 9 47  27b 11 94  27c 13 63 
28a – ND  28b – ND  28c – ND 
29a 8 >250  29b 8 >250  29c 7 >250 
30a 8 250  30b 10 >250  30c 8 >250 
31a 10 47  31b 12 94  31c 11 94 
32a 8 63  32b 9 94  32c 9 94 
33a 8 125  33b 9 250  33c 11 250 
34d 16 47  35d 15 12  36d 12 94 
Gentamicin 23 ND   MSI-78[a] ND 8-16        
ND = Not determined, [a] Literature value[25] 
concentration that completely inhibited bacterial growth as 
indicated by an OD value of equal or less than the control with no 
bacteria (Table 5). Among the tested compounds, the guanidine 
hydrochloride salt 35d showed the lowest MIC value of 12 µM 
against S. aureus. The antibacterial activity of 35d was 
comparable with the positive control compound MSI-78, which is 
a 22-amino acid AMP that is under phase III clinical trials as a 
topical antibiotic.[26] 
Structure-activity relationship studies 
The results of the biological assays were used to investigate the 
structural-activity relationships of these N-sulfonyl-
phenylglyoxamide-based compounds. Modifying the substituents 
appended to the ortho sulfonamide group had the greatest 
influence on the antibacterial activity of a compound. Among all 
synthesised compounds, only compounds with an octyl group 
(22a, 22c and 27a-27c) or 2-naphthalenyl group (29a-30c) 
appended to the ortho sulfonamide group showed antibacterial 
activity in the disk diffusion assay, whereas compounds with 
phenyl or tosyl group attached to the sulfonamide group (e.g. 19a-
20c and 23a-24c) showed no antibacterial activity. Compounds 
32a-33c bearing a butyl chain instead of an octyl chain attached 
to the sulfonamide group also showed no antibacterial activity in 
the disk diffusion assay, indicating that a longer alkyl group is 
preferred Furthermore, the MIC data showed that 
octanesulfonamide compounds had better antibacterial activity 
(MIC = 47-250 µM) than the naphthalenesulfonyl compounds 
(MIC ≥ 250 µM).  
Moreover, compounds bearing a bromine substituent at the 5-
position of the phenyl ring showed significantly higher 
antibacterial activities. For instance, 5-Br octyl compounds 27a 
and 27c showed MIC values of 47 and 63 µM against S. aureus, 
respectively, meaning that they were at least 4 times more potent 
than the parent 5-unsubstituted compounds 22a and 22c which 
both had MIC values of 250 µM (22b was not tested in the MIC 
assay). Further comparison between compounds indicated that 
antibacterial ability was diminished once the halogen was 
removed from the 5-position of the phenyl ring. Specifically, octyl 
compounds 27a-27c (5-Br), 31a-31c (5-Cl) and 32a-32c (5-F) 
showed MIC values of 47-94 µM, whereas compounds 22a,c (5-
H) and 33a-33c (5-Me) showed MIC values of 125-250 µM. 
Among the three types of halogen analogues, the bromo-
substituted compounds showed higher antibacterial activity 
compared to the fluoro or chloro compounds.  
From the disk diffusion assay (Table 5), the propylene-linked 
compounds (22a-c, 27a-c, 30a-30c) showed similar or higher 
potencies compared to the corresponding ethylene-linked 
compounds (21a-c, 26a-c, 29a-29c). However, in the MIC assay, 
the relationship between linker length and antibacterial activity 
was less clear (Table 5). For example, while the 3-carbon 
propylene glyoxamide derivative 27a (MIC = 47 µM) was more 
potent than its corresponding 2-carbon ethylene glyoxamide 
derivative 26a (MIC = 94 µM), the opposite trend was observed 
when comparing the 3-carbon propylene glyoxamide derivative 
22a (MIC = 250 µM) with the corresponding 2-carbon ethylene 
glyoxamide derivative 21a (MIC = 63 µM). 
From the MIC assay, the glyoxamide derivatives and their 
corresponding hydrochloride salts and iodide salts showed similar 
antibacterial activities, with the glyoxamide derivatives having 
slightly higher potencies than the ionic salts. Interestingly, when a 
guanidine group was installed at the end of the glyoxamide chain, 
the antibacterial activities of compounds increased significantly. 
Compounds 34d and 35d with a guanidine hydrochloride group 
showed a remarkable improvement (4-5 fold) in antibacterial 
activity compared to their corresponding glyoxamide derivatives 
22a and 27a respectively.  
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In summary, the SAR analysis for these N-sulfonyl-
phenylglyoxamides suggested that having an octyl chain on the 
sulfonamide group and a 5-bromo substituent at the phenyl ring 
were the most desirable for antibacterial activity. Moreover, while 
the glyoxamide amine derivatives showed only slightly higher 
potencies than the corresponding hydrochloride or methyl iodide 
salts, compounds with a terminal guanidine hydrochloride group 
possessed markedly enhanced antibacterial activity. Finally, no 
significant difference in potency was found between compounds 




To test how selected potent phenylglyoxamide compounds (27a, 
26b, 34d, 35d) might interact with cell membranes, tethered 
bilayer lipid membrane (tBLM) technology was used in 
conjunction with electrical impedance spectroscopy.[22b, 27] By 
anchoring a lipid membrane onto a gold substrate, it is possible 
to measure changes in intrinsic membrane conduction in real time 
upon addition of the compounds. The addition of 30% palmitoyl-
oleoyl-phosphatidylglycerol (POPG) lipids gives the membrane 
an overall negative charge as would be found in many bacterial 
cell membranes. 
Conduction versus concentration graph for the compounds is 
depicted in Figure 5. The changes in membrane conduction as a 
result of adding the molecules were compared to the response of 
a known pore-forming antimicrobial LL-37.[28] 
 
Figure 5. Conduction versus concentration graphs of selected potent compounds 27a, 
26b, 34d, 35d and LL-37 for tethered bilayer lipid membranes (tBLMs). 
The results showed that high concentrations of 
phenylglyoxamide compounds could induce an increase in 
membrane conduction in the tBLM assay. We hypothesize that 
the compounds might bind to lipid head groups and alter their 
relative packing density, which induces a change of curvature in 
lipid morphology into a more curved structure. This could induce 
lipids to relocate into membrane toroidal pore defects within lipid 
bilayers, increasing the pore surface area and thereby overall 
membrane conduction.[29]. However, although the 
phenylglyoxamide compounds had similar MIC values to LL-37 in 
the antibacterial assay (MIC = 49 µM), they showed much less 
activity than LL-37 in the tBLM assay. The increase in membrane 
conduction was observed only at relatively high concentrations of 
phenylglyoxamide (≥ 50 μM), whereas for LL-37, an effect on 
membrane conduction was evident at 1 μM. One reason for the 
lower activity of the phenylglyoxamides could be that they require 
a clustering arrangement of compounds into a certain multimeric 
state in order for pore to form. Regardless of the mechanism, the 
demonstrated increase in membrane conduction demonstrates 
the potential of these compounds to act as antimicrobial pore-
forming agents.  
 
Toxicity assay 
The in vitro toxicity of selected potent compounds (26b-c, 27a, 
34d, 35d) was determined against MRC-5 normal human lung 
fibroblasts using the Alamar blue assay.[30] A dose-response 
curve for each compound was generated to determine the IC50 
values (concentration of compound which reduced cell 
proliferation by 50% of the vehicle control). The IC50 values which 
were then used to determine the therapeutic window (IC50 value 
divided by MIC value), allowing the specificity of the compounds 
to be ranked (Figure 6, Table 6). 
 
Figure 6. In vitro anti-proliferative properties of selected potent compounds 
(26b-c, 27a, 34d, 35d) against MRC-5 normal human lung fibroblast cells after 
72 h incubation, relative to a DMSO control. 
 The glyoxamide compound 27a showed a high level of 
toxicity (IC50 = 37.4 µM) to human cells. This can be explained by 
the lack of cationic charge at the terminal group of compound 27a. 
As a consequence, compound 27a has higher hydrophobicity and 
can more easily bind to the uncharged human cell membrane. 
Compound 27a showed a therapeutic window of less than 1, 
meaning that it would be unlikely to be useful as an antibacterial 
drug. 
 While the hydrochloride salt 26b and iodide salt 26c had the 
same values, hydrochloride salt 26b (IC50 = 75.5 µM) showed a 
higher toxicity towards human cells than the iodide salt 26c (IC50 
= 328 µM). Additionally, comparison between the two guanidine 
hydrochloride salts 34d-35d showed that compound 35d (IC50 = 
178 µM) containing the more hydrophobic bromine substituent at 
the 5-position of the phenyl ring was more toxic than compound 
34d (IC50 = 373 µM) which has a hydrogen atom. This suggested 
that there might be a positive correlation between the 
hydrophobicity and the toxicity of the compounds towards human 
cells. 
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Although the guanidine hydrochloride salt 35d had a relatively low 
IC50 value compared to compounds 26c and 34d, it also had a 
significantly lower MIC value which resulted in a higher 
therapeutic window value. Overall, these data suggest that 
guanidine hydrochloride salts of glyoxamides could potentially be 
useful scaffolds for the further development of antimicrobial drugs 
to treat human bacterial infection. 
Conclusions 
This study has described an efficient synthetic and purification 
method for the preparation of N-sulfonylisatins. Twelve N-
sulfonylisatins were synthesised, and these were then ring-
opened with N,N-dimethylethane-1,2-diamine or N,N-
dimethylpropane-1,3-diamine, and subsequently converted to 
hydrochloride or iodide salts to generate a library of 30 novel small 
molecular AMP mimics. Furthermore, three guanidine 
hydrochloride mimics were also generated via ring-opening 
reaction of N-sulfonylisatins with Boc-protected amine, followed 
by Boc-deprotection and installation of the guanidine moiety. In 
vitro biological studies of analogues identified that an octyl group 
appended to ortho sulfonamide group was essential for high 
antibacterial potency. Moreover, the presence of a halogen at the 
5-position of phenyl ring and a terminal guanidine hydrochloride 
group also enhanced the antibacterial potency of the compounds. 
Guanidine hydrochloride salt 35d, possessing all three favourable 
elements, possessed the highest antibacterial potency with an 
acceptable therapeutic window. Guanidine hydrochloride salt 34d 
and iodide salt 26c also showed an acceptable therapeutic 
window despite having lower antibacterial potency. 
Mechanistically, these compounds could act as antimicrobial 
pore-forming agents as evidenced by an increase in membrane 
conduction using a tBLM assay. Thus, this novel class of 
phenylglyoxamide-based small molecular AMP mimics 
represents an innovative pathway for the development of novel 
and cost-effective antimicrobial agents. 
Experimental Section 
Chemistry 
All commercially available reagents were purchased from standard 
suppliers (Sigma Aldrich and Alfa-Aesar) and used without further 
purification. All reactions were performed under anhydrous condition with 
an atmosphere of nitrogen and anhydrous solvent unless otherwise 
specified and anhydrous solvents were obtained using PureSolv MD 
Solvent Purification System. Reactions were monitored by thin layer 
chromatography precoated with Merck silica gel 60 F254 and visualization 
was performed by using short or long wavelength of ultraviolet light. Flash 
chromatography was carried out using Grace Davisil LC60A silica. Melting 
points were measured using an OptiMelt melting point apparatus and are 
uncorrected. 1H and 13C NMR spectra were obtained in the specified 
solvents on a Bruker Avance III HD 400 or Bruker Avance III 600 Cryo 
spectrometer. Chemical shift (δ) are in parts per million (ppm) internally 
referenced to the solvent nuclei. Multiplicities are assigned as singlet (s), 
broad singlet (bs), doublet (d), triplet (t), quartet (q), quintet (quint), sextet 
(sext), septet (sept), multiplet (m) or a combination of these (e.g. dd, dt, 
td), and coupling constants (J) are described in Hertz (Hz). Infrared (IR) 
spectra were recorded using a Cary 630 FTIR spectrometer fitted with a 
diamond attenuated total reflectance (ATR) sample interface. UV-Vis 
spectra were recorded using a Cary 100 Bio double beam UV-Vis 
spectrometer in the specified solvents and data are reported as 
wavelength (λ) in nm and absorption coefficient (ε) in M−1cm−1. High-
resolution mass spectrometry (HRMS) was performed by the UNSW 
Bioanalytical Mass Spectrometry Facility using a Thermo LTQ Orbitrap XL 
instrument. 
General synthetic procedure A for N-sulfonylisatin compounds 
(7-18). To a solution of appropriate isatin (1.0 equivalent) in 
dichloromethane (10 mL) was added triethylamine (1.1 equivalents) at 0 
°C under nitrogen atmosphere. The reaction mixture was stirred at 0 °C for 
20 min. An appropriate sulfonyl chloride (1.0 equivalent) was added slowly 
to the reaction mixture at 0 °C. The reaction mixture was then stirred at 
room temperature for 3-24 h. The resulting mixture was concentrated in 
vacuo and washed with methanol to afford the product. 
General synthetic procedure B for glyoxamide derivatives and 
Boc-protected glyoxamides (19a-36a). To a solution of sulfonylisatin or 
arylisatin (1.0 equivalent) in dichloromethane (5 mL) was added an 
appropriate amine (1.0 equivalent) at 0 °C under nitrogen atmosphere. The 
reaction mixture was stirred at room temperature for 1-24 h. After 
completion of the reaction, water was added to the reaction mixture and 
the product was extracted into dichloromethane (3 × 30 mL), washed with 
brine, dried over anhydrous sodium sulfate and concentrated in vacuo to 
afford the product. 
General synthetic procedure C for hydrochloride and iodide 
salts (19b-33c). To a solution of glyoxamide derivative (1.0 equivalent) in 
dichloromethane, tetrahydrofuran or diethyl ether was added 4 M 
HCl/dioxane (5.0 equivalents) or iodomethane (2.5 equivalents). The 
reaction mixture was stirred at room temperature for 20 min to 48 h. After 
completion of reaction, the reaction mixture was concentrated in vacuo, 
washed with diethyl ether and freeze-dried to afford the product. 
General synthetic procedure D for aminoglyoxamides (34b-
36b). To a solution of Boc-protected glyoxamide (1.0 equivalent) in 
dichloromethane (10 mL) was added 4 M HCl/dioxane (3 mL). The reaction 
mixture was stirred at room temperature for 18 h. After completion of 
reaction, the reaction mixture was concentrated in vacuo and washed with 
diethyl ether to afford the product. 
General synthetic procedure E for Boc-protected guanidine 
glyoxamides (34c-36c). To a solution of aminoglyoxamides (1.0 
equivalent) and N,N'-di-Boc-1H-pyrazole-1- carboxamidine (1.2 
equivalents) in dichloromethane or acetonitrile (10 mL) was added 
triethylamine (2.5 equivalents) at 0 °C under nitrogen atmosphere. The 
reaction mixture was stirred at room temperature for 15-18 h. After 
completion of the reaction, the mixture was filtered, followed by 
concentrating in vacuo. The product was purified by flash chromatography 
on silica using ethyl acetate/n-hexane (1:4) as eluent to afford the product. 
General synthetic procedure F for guanidine hydrogen chloride 
salts (34d-36d). To a solution of Boc-protected guanidine glyoxamide (1 
equivalent) in dichloromethane (1 mL) was added trifluoroacetic acid (1 
mL). The reaction mixture was stirred at room temperature for 2 h. After 
completion of the reaction, the reaction mixture was concentrated in vacuo 
and washed with diethyl ether. To the residue in dichloromethane (1 mL) 
was added 4 M HCl/dioxane (1 mL). The reaction mixture was stirred at 
room temperature for 30 min. After completion of reaction, the reaction 
mixture was concentrated in vacuo and washed with diethyl ether to afford 
the product. 
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5-Bromo-1-(octylsulfonyl)indoline-2,3-dione (13). The title 
compound 13 was synthesised from 5-bromoisatin (1.06 g, 4.22 mmol), 
triethylamine (0.65 mL, 4.66 mmol) and octane-1-sulfonyl chloride (0.85 
mL, 4.21 mmol) following general synthetic procedure A. Reaction 
stirred for 4 h. The product 13 was obtained as a yellow solid (0.96 g, 51%); 
mp 138.0-140.1 °C; 1H NMR (400 MHz, DMSO-d6): δ 7.96-7.85 (m, 2H, 
ArH), 7.70-7.60 (m, 1H, ArH), 3.66-3.53 (m, 2H, CH2), 1.83-1.72 (m, 2H, 
CH2), 1.43-1.16 (m, 10H, CH2), 0.89-0.79 (m, 3H, CH3); 13C NMR (100 
MHz, DMSO-d6): δ 177.5 (CO), 156.0 (CO), 145.7 (ArC), 139.6 (ArCH), 
127.1 (ArCH), 121.4 (ArC), 117.2 (ArC), 116.1 (ArCH), 53.7 (CH2), 31.1 
(CH2), 28.4 (CH2), 28.3 (CH2), 27.3 (CH2), 22.1 (CH2), 22.0 (CH2), 13.9 
(CH3); IR (ATR): max 3063, 2914, 2849, 2341, 2112, 1740, 1594, 1458, 
1370, 1174, 1137, 1268, 1114, 1061, 936, 844, 720, 783 cm-1; UV-Vis 
(ACN): max 223 nm ( 18,600 cm-1 M-1), 244 (20,400), 291 (4,800), 402 
(748). 
2-(5-Bromo-2-(octylsulfonamido)phenyl)-N-(2-
(dimethylamino)ethyl)-2-oxoacetamide (26a) The title compound 38a 
was synthesised from 5-bromo-1-(octylsulfonyl)indoline-2,3-dione 13 
(0.16 g, 0.39 mmol) and N,N-dimethylethane-1,2-diamine (43 L, 0.39 
mmol) following general synthetic procedure B. Reaction stirred for 24 
h. The product 26a was obtained as a yellow oil (0.19 g, 97%); 1H NMR 
(400 MHz, CDCl3): δ 8.68-8.65 (m, 1H, ArH), 7.70-7.66 (m, 2H, ArH), 7.53 
(bs, 1H, NH), 3.50 (q, J = 5.4 Hz, 2H, CH2), 3.17-3.10 (m, 2H, CH2), 2.57 
(t, J = 5.9 Hz, 2H, CH2), 2.32 (s, 6H, CH3), 1.82-1.72 (m, 2H, CH2), 1.40-
1.18 (m, 10H, CH2), 0.86 (t, J = 6.6 Hz, 3H, CH3); 13C NMR (100 MHz, 
CDCl3): δ 190.3 (CO), 162.0 (CO), 141.0 (ArC), 139.3 (ArCH), 137.5 
(ArCH), 120.5 (ArC), 119.8 (ArCH), 115.3 (ArC), 57.3 (CH2), 52.9 (CH2), 
45.2 (CH3), 37.0 (CH2), 31.8 (CH2), 29.0 (CH2), 29.0 (CH2), 28.2 (CH2), 
23.5 (CH2), 22.7 (CH2), 14.2 (CH3); IR (ATR): max 3054, 2292, 2853, 2386, 
2102, 1649, 1525, 1460, 1388, 1331, 1285, 1193, 1146, 1099, 971, 913, 
824, 711 cm-1; UV-Vis (MeOH): max 232 nm ( 17,000 cm-1 M-1), 344 
(1,500); HRMS (+ESI): Found m/z 490.1373 [M+H]+, C20H33BrN3O4S 
required 490.1370. 
2-(2-(5-Bromo-2-(octylsulfonamido)phenyl)-2-oxoacetamido)-
N,N-dimethylethan-1-aminium chloride (26b). The title compound 26b 
was synthesised from 2-(5-bromo-2-(octylsulfonamido)phenyl)-N-(2-
(dimethylamino)ethyl)-2-oxoacetamide 26a (20 mg, 0.041 mmol) and 4 M 
HCl/dioxane (0.10 mL, 0.40 mmol) in diethyl ether (10 mL) following 
general synthetic procedure C. Reaction stirred for 20 min. The product 
26b was obtained as a white sticky solid (19 mg, 88%); 1H NMR (400 MHz, 
DMSO-d6): δ 10.24 (bs, 1H, NH), 9.99 (bs, 1H, NH), 9.09 (t, J = 5.8 Hz, 
1H, NH), 7.99 (d, J = 2.4 Hz, 1H, ArH), 7.84 (dd, J = 8.8, 2.5 Hz, 1H, ArH), 
7.44 (d, J = 8.8 Hz, 1H, ArH), 3.58 (q, J = 6.0 Hz, 2H, CH2), 3.29-3.23 (m, 
2H, CH2), 3.20-3.13 (m, 2H, CH2), 2.81 (s, 6H, CH3), 1.69-1.59 (m, 2H, 
CH2), 1.37-1.16 (m, 10H, CH2), 0.84 (t, J = 6.6 Hz, 3H, CH3); 13C NMR 
(100 MHz, DMSO-d6): δ 189.0 (CO), 162.4 (CO), 137.2 (ArC), 136.7 
(ArCH), 134.2 (ArCH), 128.4 (ArC), 124.6 (ArCH), 116.2 (ArC), 55.1 (CH2), 
51.6 (CH2), 42.3 (CH3), 34.2 (CH2), 31.1 (CH2), 28.4 (CH2), 28.3 (CH2), 
27.3 (CH2), 22.8 (CH2), 22.0 (CH2), 13.9 (CH3); IR (ATR): max 3258, 2922, 
2852, 2695, 2106, 1671, 1529, 1488, 1389, 1331, 1199, 1140, 1093, 1019, 
914, 830, 764, 700 cm-1; UV-Vis (H2O): max 231 nm ( 15,000 cm-1 M-1); 
HRMS (+ESI): Found m/z 490.1373 [M+H]+, C20H33BrN3O4S required 
490.1370. 
2-(2-(5-Bromo-2-(octylsulfonamido)phenyl)-2-oxoacetamido)-
N,N,N-trimethylethan-1-aminium iodide (26c). The title compound 26c 
was synthesised from 2-(5-bromo-2-(octylsulfonamido)phenyl)-N-(2-
(dimethylamino) ethyl)-2-oxoacetamide 26a (31 mg, 0.063 mmol) and 
iodomethane (12 L, 0.19 mmol) in tetrahydrofuran (3 mL) following 
general synthetic procedure C. Reaction stirred for 18 h. The product 
26c was obtained as a yellow sticky solid (39 mg, 97%); 1H NMR (400 MHz, 
DMSO-d6): δ 9.97 (bs, 1H, NH), 9.13 (t, J = 5.7 Hz, 1H, NH), 7.93-7.82 (m, 
2H, ArH), 7.41 (d, J = 8.6 Hz, 1H, ArH), 7.36-7.31 (m, 1H, ArH), 3.65 (q, J 
= 6.0 Hz, 2H, CH2), 3.50 (t, J = 6.2 Hz, 2H, CH2), 3.20-3.07 (m, 11H, CH2, 
CH3), 1.68-1.58 (m, 2H, CH2), 1.36-1.14 (m, 10H, CH2), 0.84 (t, J = 6.7 Hz, 
3H, CH3); 13C NMR (150 MHz, DMSO-d6): δ 189.3 (CO), 162.8 (CO), 137.2 
(ArC), 136.9 (ArCH), 133.9 (ArCH), 129.1 (ArC), 125.2 (ArCH), 116.8 (ArC), 
63.5 (CH2), 52.7 (CH3), 51.3 (CH2), 33.5 (CH2), 31.1 (CH2), 28.4 (CH2), 
28.3 (CH2), 27.3 (CH2), 22.8 (CH2), 22.0 (CH2), 14.0 (CH3); IR (ATR): max 
3366, 3276, 2921, 2852, 2321, 2100, 1647, 1478, 1386, 1334, 1316, 1195, 
1146, 1040, 976, 916, 818, 722 cm-1; UV-Vis (H2O): max 228 nm ( 30,000 
cm-1 M-1); HRMS (+ESI): Found m/z 504.1526 [M]+, C21H35BrN3O4S 
required 504.1526. 
2-(5-Bromo-2-(octylsulfonamido)phenyl)-N-(3-(dimethylamino) 
propyl)-2-oxoacetamide (27a). The title compound 27a was synthesised 
from 5-bromo-1-(octylsulfonyl)indoline-2,3-dione 13 (0.15 g, 0.39 mmol) 
and N,N-dimethylpropane-1,3-diamine (49 L, 0.39 mmol) following 
general synthetic procedure B. Reaction stirred for 18 h. The product 
27a was obtained as a yellow oil (0.37 g, 97%); 1H NMR (400 MHz, CDCl3): 
δ 8.89 (bs, 1H, NH), 8.62 (t, J = 1.3 Hz, 1H, ArH), 7.69-7.66 (m, 2H, ArH), 
3.52 (t, J = 6.0 Hz, 2H, CH2), 3.15-3.10 (m, 2H, CH2), 2.56 (t, J = 6.1 Hz, 
2H, CH2), 2.34 (s, 6H, CH3), 1.84-1.73 (m, 4H, CH2), 1.40-1.18 (m, 10H, 
CH2), 0.86 (t, J = 6.6 Hz, 3H, CH3); 13C NMR (100 MHz, CDCl3): δ 190.8 
(CO), 162.2 (CO), 140.8 (ArC), 139.1 (ArCH), 137.4 (ArCH), 120.9 (ArC), 
120.0 (ArCH), 115.4 (ArC), 58.8 (CH2), 52.8 (CH2), 45.2 (CH3), 40.0 (CH2), 
31.8 (CH2), 29.1 (CH2), 29.0 (CH2), 28.2 (CH2), 25.1 (CH2), 23.5 (CH2), 
22.7 (CH2), 14.2 (CH3); IR (ATR): max 3258, 3049, 2922, 2853, 2521, 2112, 
1897, 1650, 1529, 1460, 1388, 1287, 1146, 1194, 1099, 972, 915, 823, 
710 cm-1; UV-Vis (MeOH): max 231 nm ( 24,100 cm-1 M-1), 343 (1,610); 
HRMS (+ESI): Found m/z 504.1528 [M+H]+, C21H35BrN3O4S required 
504.1526. 
tert-Butyl(3-(2-(5-bromo-2-(octylsulfonamido)phenyl)-2-
oxoacetamido)propyl) carbamate (35a). The title compound 35a was 
synthesised from 5-bromo-1-(octylsulfonyl)indoline-2,3-dione 13 (0.21 g, 
0.51 mmol) and tert-butyl (3-aminopropyl)carbamate (92 mg, 0.51 mmol) 
following general synthetic procedure B. Reaction stirred for 21 h. The 
product 35a was obtained as a yellow oil (0.29 g, 98%); 1H NMR (400 MHz, 
CDCl3): δ 10.39 (bs, 1H, NH), 8.70-8.63 (m, 1H, ArH), 7.76 (bs, 1H, NH), 
7.72-7.66 (m, 2H, ArH), 4.80 (bs, 1H, NH), 3.46 (q, J = 6.4 Hz, 2H, CH2), 
3.24 (q, J = 5.8 Hz, 2H, CH2), 3.16-3.11 (m, 2H, CH2), 1.83-1.70 (m, 4H, 
CH2), 1.45 (s, 9H, CH3), 1.40-1.19 (m, 10H, CH2), 0.86 (t, J = 6.7 Hz, 3H, 
CH3); 13C NMR (100 MHz, CDCl3): δ 190.4 (CO), 162.2 (CO), 157.0 (CO), 
141.0 (ArC), 139.3 (ArCH), 137.5 (ArCH), 120.4 (ArC), 119.8 (ArCH), 
115.2 (ArC), 80.0 (C), 52.9 (CH2), 37.2 (CH2), 36.4 (CH2), 31.8 (CH2), 30.2 
(CH2), 29.0 (CH2), 29.0 (CH2), 28.5 (CH3), 28.2 (CH2), 23.5 (CH2), 22.7 
(CH2), 14.2 (CH3); IR (ATR): max 3226, 3176, 2922, 2852, 2318, 2117, 
1684, 1631, 1519, 1479, 1390, 1334, 1247, 1136, 1010, 914, 835, 723 cm-
1; UV-Vis (MeOH): max 231 nm ( 19,000 cm-1 M-1), 347 (950); HRMS 
(+ESI): Found m/z 598.1559 [M+Na]+, C24H38BrN3O6SNa required 
598.1557. 
N-(3-Aminopropyl)-2-(5-bromo-2-(octylsulfonamido)phenyl)-2-
oxoacetamide hydrochloride (35b). The title compound 35b was 
synthesised from tert-butyl (3-(2-(5-bromo-2-(octylsulfonamido)phenyl)-2-
oxoacetamido)propyl)carbamate 35a (0.26 g, 0.45 mmol) following 
general synthetic procedure D. The product 35b was obtained as a 
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yellow sticky solid (0.19 g, 83%); 1H NMR (400 MHz, DMSO-d6): δ 10.08 
(bs, 1H, NH), 8.99 (t, J = 5.8 Hz, 1H, NH), 8.12 (bs, 1H, NH), 7.96 (bs, 2H, 
NH), 7.90-7.83 (m, 2H, ArH), 7.46 (d, J = 8.7 Hz, 1H, ArH), 3.32-3.26 (m, 
2H, CH2), 3.20-3.15 (m, 2H, CH2), 2.91-2.80 (m, 2H, CH2), 1.87-1.78 (m, 
2H, CH2), 1.68-1.59 (m, 2H, CH2), 1.36-1.16 (m, 10H, CH2), 0.84 (t, J = 6.8 
Hz, 3H, CH3); 13C NMR (100 MHz, DMSO-d6): δ 190.3 (CO), 162.9 (CO), 
137.6 (ArC), 137.0 (ArCH), 134.2 (ArCH), 127.7 (ArC), 124.3 (ArCH), 
116.2 (ArC), 51.4 (CH2), 36.6 (CH2), 35.9 (CH2), 31.1 (CH2), 28.3 (CH2), 
28.3 (CH2), 27.3 (CH2), 26.8 (CH2), 22.8 (CH2), 22.0 (CH2), 13.9 (CH3); IR 
(ATR): max 3329, 3252, 2920, 2047, 1640, 1523, 1475, 1385, 1334, 1256, 
1195, 1141, 1019, 916, 818, 762, 715 cm-1; UV-Vis (H2O): max 231 nm ( 
19,000 cm-1 M-1), 368 (790); HRMS (+ESI): Found m/z 476.1215 [M+H]+, 




carbamimidoyl)-1-(tert-butyl)-oxidanecarboxamide (35c). The title 
compound 35c was synthesised from  N-(3-aminopropyl)-2-(5-bromo-2-
(octylsulfonamido)phenyl)-2-oxoacetamide hydrochloride 35b (0.11 g, 
0.20 mmol), triethylamine (70 L, 0.50 mmol) and N,N'-di-Boc-1H-
pyrazole-1- carboxamidine (72 mg, 0.23 mmol) in acetonitrile (10 mL) 
following general synthetic procedure E. Reaction stirred for 15 h. The 
product 35c was obtained as a yellow oil (74 mg, 51%); 1H NMR (400 MHz, 
CDCl3): δ 11.47 (bs, 1H, NH), 10.52 (bs, 1H, NH), 8.68 (t, J = 5.9 Hz, 1H, 
NH), 8.52 (t, J = 6.2 Hz, 1H, NH), 8.46 (d, J = 2.0 Hz, 1H, ArH), 7.72-7.65 
(m, 2H, ArH), 3.54 (q, J = 6.4 Hz, 2H, CH2), 3.44 (q, J = 6.0 Hz, 2H, CH2), 
3.15-3.09 (m, 2H, CH2), 1.83-1.72 (m, 4H, CH2), 1.50 (s, 9H, CH3), 1.40-
1.19 (m, 19H, CH2, CH3), 0.86 (t, J = 6.7 Hz, 3H, CH3); 13C NMR (100 MHz, 
CDCl3): δ 191.4 (CO), 163.1 (CO), 163.0 (CN), 157.5 (CO), 153.4 (CO), 
141.1 (ArC), 139.2 (ArCH), 137.3 (ArCH), 120.0 (ArC), 119.6 (ArCH), 
115.1 (ArC), 83.8 (C), 79.7 (C), 52.9 (CH2), 37.1 (CH2), 35.8 (CH2), 31.8 
(CH2), 30.1 (CH2), 29.0 (CH2), 29.0 (CH2), 28.3 (CH3), 28.2 (CH2), 28.2 
(CH3), 23.5 (CH2), 22.7 (CH2), 14.2 (CH3); IR (ATR): max 3328, 3190, 2925, 
2091, 1722, 1620, 1571, 1477, 1412, 1328, 1284, 1130, 1050, 1025, 903, 
815, 767, 711 cm-1; UV-Vis (MeOH): max 233 nm ( 64,000 cm-1 M-1), 368 
(1,200); HRMS (+ESI): Found m/z 718.2480 [M+H]+, C30H49BrN5O8S 
required 718.2480. 
2-(5-Bromo-2-(octylsulfonamido)phenyl)-N-(3-
guanidinopropyl)-2-oxoacetamide hydrochloride (35d). The title 
compound 35d was synthesised from (E)-N-(N-(3-(2-(5-bromo-2-
(octylsulfonamido)phenyl)-2-oxoacetamido)propyl)-N'-((tert-
butyloxidanyl)carbonyl)carbamimidoyl)-1-(tert-butyl)-oxidanecarboxamide 
35c (30 mg, 0.042 mmol) following general synthetic procedure F. The 
product 35d was obtained as a yellow sticky solid (17 mg, 72%); 1H NMR 
(600 MHz, DMSO-d6): δ 10.07 (bs, 1H, NH), 8.94 (bs, 1H, NH), 7.91-7.82 
(m, 2H, ArH), 7.64 (t, J = 5.3 Hz, 1H, NH), 7.45 (d, J = 8.7 Hz, 1H, ArH), 
7.34 (bs, 2H, NH), 7.03 (bs, 2H, NH), 3.26 (q, J = 6.6 Hz, 2H, CH2), 3.20-
3.15 (m, 4H, CH2), 1.75-1.69 (m, 2H, CH2), 1.66-1.60 (m, 2H, CH2), 1.35-
1.17 (m, 10H, CH2), 0.84 (t, J = 7.0 Hz, 3H, CH3); 13C NMR (150 MHz, 
DMSO-d6): δ 190.5 (CO), 163.0 (CO), 156.9 (CN), 137.7 (ArC), 137.0 
(ArCH), 134.2 (ArCH), 127.6 (ArC), 124.2 (ArCH), 116.2 (ArC), 51.4 (CH2), 
38.3 (CH2), 36.1 (CH2), 31.1 (CH2), 28.4 (CH2), 28.3 (CH2), 28.3 (CH2), 
27.3 (CH2), 22.8 (CH2), 22.0 (CH2), 13.9 (CH3); IR (ATR): max 3337, 3178, 
2923, 2852, 2101, 1640, 1523, 1477, 1384, 1326, 1135, 1051, 1026, 902, 
817, 770, 711 cm-1; UV-Vis (H2O): max 231 nm ( 21,000 cm-1 M-1), 368 
(960); HRMS (+ESI): Found m/z 518.1425 [M+H]+, C20H33BrN5O4S 
required 518.1431. 
 
Disk diffusion assay 
The disk diffusion method was used to initially evaluate the antibacterial 
potential of the test compounds against S. aureus (strain 38) and P. 
aeruginosa (PAO1). Overnight cultures of bacteria were prepared in 
tryptone soya broth (TSB; Oxoid, UK) at 37 °C and the resulting bacterial 
cultures (200 µL) were spread onto nutrient agar plates. The compounds 
to be tested were dissolved in DMSO and dried on sterile 6 mm diameter 
paper disks (80 nmol per disk), and placed onto nutrient agar plates. Sterile 
disks loaded with gentamicin (0.01 mg per disk) were used as positive 
control. After incubation at 37 °C for 24 h, the diameter of the inhibition 
zone was measured to the nearest 1.0 mm. 
 
Minimal inhibitory concentration (MIC) assay 
Compounds that were shown active from disk diffusion assay were further 
assessed by determining their minimum inhibitory concentration (MIC) 
according to a previously published protocol.[31] A single colony of bacteria 
was cultured overnight in TSB at 37 °C. The resulting bacterial culture was 
collected by centrifugation and re-suspended in TSB twice. The optical 
density (OD) of the resulting culture was adjusted to OD600 = 0.1 in TSB 
(equivalent to 108 colony forming unit (CFU)/mL bacteria), and was further 
diluted to 105 CFU/mL in TSB. 100 µL of the bacterial solution was then 
added to wells of a 96-well plate containing 100 µL serially diluted 
compound, with final concentration ranging from 8-250 µM. The plates 
were then incubated at 37 ˚C for 24 h and the data was recorded by 
measuring the OD value at 600 nm using a Wallac Victor (Perkin-Elmer) 
microplate reader. The MIC value of each compound was determined as 
the lowest concentration that completely inhibited the growth of bacteria. 
Each experiment was performed in triplicate and was repeated in two 
independent experiments. 
 
Tethered bilayer lipid membrane assay 
Tethered bilayer lipid membranes (tBLMs) in association with alternating 
current electrical impedance spectroscopy techniques were employed to 
determine if the compounds are lytic to cell membranes. Sparsely tethered 
tBLMs were created using the solvent exchange technique described 
previously.[32] In short, pre-prepared tethered benzyl-disulfide (tetra-
ethyleneglycol) n = 2 C20-phytanyl tethers benzyl-disulfide-tetra-
ethyleneglycol-OH spacers in the ratio of 1:10 were coated onto a gold 
patterned polycarbonate slide (SDx Tethered Membranes Pty Ltd, 
Australia). Using a specialised cartridge chamber, a 3 mM solution of a 
standard mobile lipid phase [70% zwitterionic C20 Diphytanyl-Glycero-
Phosphatidylcholine lipid: 30% C20 Diphytanyl-diglyceride-OH ether] 
supplemented with 30% palmitoyl-oleoyl-phosphatidylglycerol (POPG) 
(Avanti Lipids, USA) was added to the tethering chemistries to create 
negatively charged membranes like those present in bacterial species. All 
lipids were dissolved in 100% ethanol. Lipids were left for 2 minutes to 
associate with the tethering chemistries before being washed with 3 × 200 
mL phosphate buffered saline (PBS). AC impedance spectrometry was 
then employed to verify the presence of the tethered lipid bilayers and to 




Normal human lung fibroblasts MRC-5 were cultured in minimal essential 
medium (MEM, Invitrogen) supplemented with 10% foetal calf serum, 2% 
sodium bicarbonate, 1% L-glutamine-penicillin-streptomycin, 1% non-
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essential amino acids (NEAA) and 1% sodium pyruvate. The cell line was 
maintained at 37 °C in 5% CO2 as an adherent monolayer and was 
passaged upon reaching confluence by standard cell culture techniques. 
MRC-5 cells were then seeded at 2 × 104 cells per well in 96-well plates to 
ensure full confluence (quiescence). 24 h after seeding, cells were treated 
with 0.1 to 500 μM of compounds. After 72 h incubation, the treated media 
was replaced with fresh media containing 10% Alamar blue and the cells 
were incubated for another 6 h. The metabolic activity was detected by 
spectrophotometric analysis by assessing the absorbance of Alamar blue 
as previously described by O’Brien et al.[30] Cell proliferation was 
determined and expressed as a percentage of untreated control cells. The 
IC50 values were determined using GraphPad Prism 6. 
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